Business Context and Reporting Period
Company: Rentokil Initial plc
Filing Type: Form 6-K (Preliminary Results)
Reporting Period: Full Year ended 31 December 2023
Announcement Date: 7 March 2024
Overview: Rentokil Initial reported strong operational and financial performance for 2023, driven by the full-year inclusion of the Terminix acquisition and organic growth across most regions. The company launched the "RIGHT WAY 2" plan to address slower organic growth in North America and increased its synergy targets for the Terminix integration.
Key Financial Metrics
| Metric | 2023 (£m) | 2022 (£m) | Change (%) |
|---|---|---|---|
| Revenue (AER) | 5,375 | 3,714 | 44.7% |
| Revenue (CER) | 5,414 | 3,714 | 45.8% |
| Organic Revenue Growth | 4.9% (excl. COVID disinfection) | ||
| Adjusted EBITDA | 1,228 | 859 | 43.0% |
| Adjusted Operating Profit | 898 | 571 | 57.1% |
| Adjusted Operating Margin | 16.6% | 15.4% | +120 bps |
| Statutory Operating Profit | 625 | 317 | 96.9% |
| Profit Before Tax (Statutory) | 493 | 296 | 66.9% |
| Free Cash Flow | 500 | 374 | 33.7% |
| Adjusted Free Cash Flow Conversion | 89.4% | 91.8% | - |
| Diluted Adjusted EPS | 23.08p | 21.22p | 8.8% |
| Statutory EPS | 15.14p | 11.57p | 30.8% |
| Net Debt to EBITDA | 2.8x | 4.6x | - |
| Dividend Per Share (Total FY23) | 8.68p | 7.55p | 15.0% |
Material Changes vs. Prior Period
- Terminix Acquisition Impact: The full-year inclusion of Terminix significantly boosted North America revenue (up 79.2% at CER) and Adjusted Operating Profit (up 95.9%).
- Margin Expansion: Group Adjusted Operating Margin improved by 120 basis points to 16.6%, driven by Terminix synergies (100bps contribution) and effective pricing strategies offsetting inflation.
- Regional Performance:
- North America: Organic revenue growth of 3.1% was below expectations due to lower new business lead generation in H2.
- Europe (incl. LATAM): Strong organic growth of 9.2% supported by price increases and demand resilience.
- France Workwear: Delivered 13.2% organic revenue growth.
- Hygiene & Wellbeing: Full-year margin decreased by 130bps to 18.5% due to the drop in COVID disinfection revenues (from £21m in 2022 to £2m in 2023), though H2 margins recovered to above 19.0%.
- Deleveraging: Net debt to EBITDA ratio improved to 2.8x, one year ahead of the company's target.
Guidance, Outlook, and Strategic Initiatives
RIGHT WAY 2 Plan (North America)
Launched to reinvigorate organic growth in North America following a review of H2 underperformance. Key actions include:
- Investment of c.$25m in sales and marketing.
- Strengthening sales effectiveness and frontline colleague retention.
- Rollout of the "Trusted Advisor" programme to increase technician-led sales.
- Expectation of c.2% organic revenue growth in Q1 2024 and 2-4% for the full year.
Terminix Integration Update
- Synergy Targets Raised: Gross synergy target increased by $50m to $325m; Net synergy target increased to $225m.
- Timeline: Integration completion revised to 2026 to de-risk branch integrations.
- 2024 Outlook: Expected to deliver c.$40m of net cost synergies in FY24.
Financial Outlook for 2024
- Revenue: Expect good underlying trading momentum despite macro headwinds.
- Margins: Modest North America margin progression expected, weighted to H2. Medium-term Group margin target of >19% expected to be achieved in 2026.
- M&A: Anticipated spend of c.£250m on bolt-on acquisitions.
- Cash Flow: Adjusted free cash flow conversion forecast between 80-90%.
- Dividend: Recommended final dividend of 5.93p (Total FY23: 8.68p).
Risks and Contingencies
- Paragon Distribution Closure: The Paragon business (acquired with Terminix) will close on 1 April 2024 due to a discontinued supplier relationship, reducing 2024 North America revenue by ~$61m and Adjusted Operating Profit by ~$4m.
- Termite Claims: Legacy termite warranty claims remain a risk, though filed claims reduced by 14% in 2023. A $250,000 cap has been introduced for new residential customers.
- Macroeconomic Factors: Inflationary pressures, labor market tightness, and foreign exchange fluctuations.
Investor Verification Checklist
- North America Organic Growth: Verify the effectiveness of the "RIGHT WAY 2" plan in Q1 and Q2 2024 to ensure the 2-4% full-year organic growth target is met.
- Terminix Synergy Realization: Monitor the delivery of the revised $40m net synergy target for 2024 and the progress of branch integrations.
- Paragon Closure Impact: Confirm the financial impact of the Paragon business closure aligns with the stated $61m revenue and $4m profit reduction in 2024.
- Hygiene Margins: Track the Hygiene & Wellbeing margin profile to ensure it remains stable above 19% in H2 2024 as guided.
- Debt Refinancing: Watch for the refinancing of the €400m bond maturing in November 2024 and its impact on interest costs.